A Phase 1/2 interventional study of Brentuximab vedotin and Doxorubicin in Hodgkin Disease, sponsored by Takeda. Active, not recruiting at 14 sites in 4 countries. Open to participants aged 5 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Takeda · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 80 studies testing Brentuximab Vedotin in Hodgkin Disease — 14 open to participants now, 28 under way, 8 of them phase 3. Brentuximab Vedotin · Hodgkin Disease.
Among the 80 studies testing Brentuximab Vedotin in Hodgkin Disease, this one is the 35th largest by enrollment, is one of 5 that started in 2017, is one of 12 in phase 1/2, reaches primary completion later than 1 of the 27 other live ones, and was the 50th registered.
1,383 studies on the registry are indexed under Hodgkin Disease; 163 are open to participants now.
Browse Hodgkin Disease studies →14 of the 80 studies testing Brentuximab Vedotin in Hodgkin Disease are open now, in 12 countries. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
University of Miami · Sites in United States
Ages 18–60
Children's Cancer Group, China · Sites in China
Ages 2–35
Takeda · Sites in India
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Brentuximab Vedotin: first FDA approval 2011 (ADCETRIS), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 136 Hodgkin Disease studies recruiting now, 73 (54%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.
This study: 5 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
80 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 56 · Phase 3 11 · Phase 4 2
First in 2006; this study’s year is marked. 5 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 59 is above the median of 40 across 1,095 interventional studies indexed under Hodgkin Disease.
Median enrollment 52 across the 80 interventional studies. Of the 46 that completed or were terminated, 26 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 80 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
15 studies in Hodgkin Disease by Takeda: 3 open now, 4 under way, none of them phase 3. Of 10 finished, 6 (60%) have results posted.
Among the 15 studies in Hodgkin Disease by Takeda, this one is the only one that started in 2017, is one of 2 in phase 1/2, and was the 8th registered.
Takeda’s Hodgkin Disease studies by the year they started, since 1997.
7 of the studies testing Brentuximab Vedotin in Hodgkin Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05180097Canadian Cancer Trials GroupPembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma | 2026-12-31 |
| NCT03755804St. Jude Children's Research HospitalPediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17 | 2027-01-01 |
| NCT06377566Memorial Sloan Kettering Cancer CenterA Study of BV-AVD in People With Bulky Hodgkin Lymphoma | 2027-04 |
| NCT04561206City of Hope Medical CenterBrentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma | 2027-10-02 |
| NCT05404945University of VirginiaFitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above | 2027-10-03 |
Add all 7 to your calendar (.ics) → With an account.
Among the 80 studies testing Brentuximab Vedotin in Hodgkin Disease, from their registry updates:
Among Takeda’s 15 in Hodgkin Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety, tolerability, and anti-tumor activity, as well as confirm the recommended dose of brentuximab vedotin (ADCETRIS) in combination with a multiagent chemotherapy regimen, doxorubicin (Adriamycin), vinblastine, and dacarbazine, in pediatric participants with advanced stage newly diagnosed classical CD30+ Hodgkin Lymphoma (HL).
The drug being tested in this study is called brentuximab vedotin. Brentuximab vedotin is being tested to treat pediatric participants who have advanced stage, newly diagnosed, classical CD30+ HL. This study will assess the safety, tolerability, and anti-tumor activity, as well as recommended dose of brentuximab vedotin in combination with a multiagent chemotherapy regimen that is based on a current standard of care (SOC) first-line treatment regimen for newly diagnosed HL.
The study will enroll approximately 55 evaluable participants. The study will be conducted in 2 phases, Phase 1 and Phase 2. Phase 1 study will enroll at least 6 participants to determine the recommended dose. Once the recommended dose is identified additional participants will be enrolled into phase 2 so that the total number of evaluable participants will be at least 55, including participants treated at recommended dose in Phase 1. Participants will be enrolled to the following initial dose cohort with an option to explore a reduced dose cohort at 36 mg/m\^2 if needed:
This multi-center trial will be conducted in the United States, Italy, Brazil and Japan. The overall time to participate in this study is approximately 55 months, including the follow-up period. Participants will be followed for a maximum of 30 days following the last dose of protocol therapy for a follow-up assessment and will be followed for survival and disease status every 12 weeks for 12 months, and then every 24 weeks until death or study closure or for up to 2 years from the date of the last participant enrolled.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Each participant must meet all the following inclusion criteria to be enrolled in the study:
Exclusion Criteria:
Any of the following cardiovascular conditions or values within 6 months before the first dose of protocol therapy:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brentuximab vedotin 48 mg/m\^2 (A), intravenous infusion, once on Days 1 and 15 of each 28-day cycle approximately 1 hour after administration of doxorubicin 25 mg/m\^2, vinblastine 6 mg/m\^2, and dacarbazine 375 mg/m\^2 (AVD), intravenous infusion, once on Days 1 and 15 of each 28-day cycle for up to 6 cycles.
Drug: Brentuximab vedotin · Drug: Doxorubicin · Drug: Vinblastine · Drug: Dacarbazine
Brentuximab vedotin 48 mg/m\^2 (A), intravenous infusion, once on Days 1 and 15 of each 28-day cycle approximately 1 hour after administration of doxorubicin 25 mg/m\^2, vinblastine 6 mg/m\^2, and dacarbazine 375 mg/m\^2 (AVD), intravenous infusion, once on Days 1 and 15 of each 28-day cycle for up to 6 cycles.
Drug: Brentuximab vedotin · Drug: Doxorubicin · Drug: Vinblastine · Drug: Dacarbazine
Brentuximab vedotin infusion
Also known as: Adcetris
Doxorubicin infusion
Also known as: Adriamycin
Vinblastine infusion
Dacarbazine infusion
Phase 1: Recommended Dose of Brentuximab Vedotin in Combination With Doxorubicin, Vinblastine, and Dacarbazine in a Pediatric Population
The recommended dose was determined after considering all safety data in phase 1 and assessing for dose limiting toxicities (DLTs) which are defined as the dose range at which less than or equal to (\<=) 1 of 6 evaluable participants experience DLT within the defined observation period (Cycle 1 + 28 days). This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.
Time frame: From the first dose (Cycle 1) up to Day 56 (Cycle length=28 days)
Phase 1: Percentage of Participants Who Experienced Adverse Events (AEs) From the First Dose of Protocol Therapy Through 30 Days After Administration of the Last Dose of Protocol Therapy
AE means any untoward medical occurrence in a participant administered a pharmaceutical product; the untoward medical occurrence does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product whether or not it is related to the medicinal product. This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.
Time frame: From first dose in Cycle 1 Day 1 until 30 days after the last dose of study drug in Cycle 6 Day 15 (up to Cycle 7 Day 15) (Cycle length=28 days)
Phase 1: Percentage of Participants Who Experienced Serious Adverse Events (SAEs) From the First Dose of Protocol Therapy Through 30 Days After Administration of the Last Dose of Protocol Therapy
AE means any untoward medical occurrence in a participant administered a pharmaceutical product; the untoward medical occurrence does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product whether or not it is related to the medicinal product. SAE is defined as any untoward medical occurrence that at any dose results in death, Is life-threatening, requires inpatient hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability or incapacity, Is a congenital anomaly/birth defect, Is a medically important event.
Time frame: From first dose in Cycle 1 Day 1 until 30 days after the last dose of study drug in Cycle 6 Day 15 (up to Cycle 7 Day 15) (Cycle length=28 days)
Phase 2: Percentage of Participants Who Achieved a Complete Remission (CR) Per Independent Review Facility (IRF) Assessment Per International Working Group (IWG) Criteria at End of Treatment (EOT) Visit
CR was defined as the disappearance of all evidence of disease as assessed by IRF as per IWG Criteria. The confidence interval was based on exact binomial distribution (Clopper-Pearson method). This outcome measure was planned to be assessed for all participants treated at the recommended dose in Phase 2. As prespecified in the statistical analysis plan (SAP) , data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
Time frame: At end of treatment (EOT) visit 30 days after the last dose of study drug (at Month 7)
Phase 2: Percentage of Participants Whose Disease Was Positron Emission Tomography (PET) Negative After 2 Cycles of Protocol Therapy Per IRF Assessment
The Deauville score according to IRF assessment of response was used to evaluate the results of PET scans. PET negative after Cycle 2 was defined as an IRF Deauville score of (1 or 2 or 3). This outcome measure was planned to be assessed for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
Time frame: From first dose of study drug up to Cycle 2 Day 25 (Each Cycle length=28 days)
Phase 2: Percentage of Participants Who Achieved a Partial Remission (PR) Per IRF Assessment Per IWG Criteria at EOT Visit
PR was defined as regression of measurable disease and no new sites as assessed by IRF as per IWG criteria. Percentage of participants in the response-evaluable population who achieved a partial response based on the IRF assessment at the EOT visit based on the IWG criteria are reported. The confidence interval was based on exact binomial distribution (Clopper-Pearson method). This outcome measure was planned to be assessed for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
Time frame: At EOT visit 30 days after the last dose of study drug (at Month 7)
Phase 2: Percentage of Participants Who Achieved an Overall Response Rate (ORR) Per IRF Assessment Per IWG Criteria at EOT Visit
Overall response rate was defined as the percentage of participants with CR or PR as assessed by IRF using IWG criteria. CR was defined as the disappearance of all evidence of disease and PR was defined as regression of measurable disease and no new diseases. The confidence interval was based on exact binomial distribution (Clopper-Pearson method). This outcome measure was planned to be assessed for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
Time frame: At EOT visit 30 days after the last dose of study drug (at Month 7)
Phase 2: Percentage of Participants Who Were Able to Complete 6 Cycles of Protocol Therapy at the Recommended Dose
This outcome measure was planned to be assessed for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
Time frame: From first dose of study drug up to Cycle 6 (Each Cycle length=28 days)
Phase 1: Mean Maximum Observed Serum Concentration (Cmax) of Brentuximab Vedotin Total Conjugated and Therapeutic Antibody (TAb)
This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.
Time frame: Days 1 and 15 of Cycles 1 and 3 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)
Phase 1: Mean Maximum Observed Plasma Concentration (Cmax) of Monomethyl Auristatin E (MMAE)
This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.
Time frame: Days 1 and 15 of Cycles 1 and 3 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)
Phase 1: Mean Area Under the Serum Concentration-Time Curve From Day 0 to Day 15 (AUC0-15) of Brentuximab Vedotin and TAb
This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.
Time frame: Days 1 and 15 of Cycles 1 and 3 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)
Phase 1: Mean Area Under the Plasma Concentration-Time Curve From Day 0 to Day 15 (AUC0-15) of MMAE
This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.
Time frame: Days 1 and 15 of Cycles 1 and 3 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)
Phase 1: Median Time to Reach Cmax (Tmax) of Brentuximab Vedotin and TAb in Serum
This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.
Time frame: Cycle 1-6: Days 1 and 15 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)
Phase 1: Median Time to Reach Cmax (Tmax) of MMAE in Plasma
This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.
Time frame: Days 1 and 15 of Cycles 1 and 3 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)
Phase 1: Percentage of Participants Who Achieved a CR Per IRF Assessment Per IWG Criteria at EOT Visit
CR was defined as the disappearance of all evidence of disease as assessed by IRF as per IWG Criteria. The confidence interval was based on exact binomial distribution (Clopper-Pearson method). This outcome measure was planned to be assessed only for participants treated in Phase 1 arm.
Time frame: At EOT visit 30 days after the last dose of study drug (at Month 7)
Phase 1: Percentage of Participants Who Achieved a PR Per IRF Assessment Per IWG Criteria at EOT Visit
PR was defined as regression of measurable disease and no new diseases as per IWG Criteria based on IRF. The confidence interval was based on exact binomial distribution (Clopper-Pearson method). This outcome measure was planned to be assessed only for participants treated in Phase 1 arm.
Time frame: At EOT visit 30 days after the last dose of study drug (at Month 7)
Phase 1: Percentage of Participants Who Achieved an ORR Per IRF Assessment Per IWG Criteria at EOT Visit
Overall response rate was defined as the percentage of participants with CR or PR as assessed by an IRF using IWG Revised Response Criteria. CR was defined as the disappearance of all evidence of disease and PR was defined as regression of measurable disease and no new sites. The confidence interval was based on exact binomial distribution (Clopper-Pearson method). This outcome measure was planned to be assessed only for participants treated in Phase 1 arm.
Time frame: At EOT visit 30 days after the last dose of study drug (at Month 7)
Phase 1: Percentage of Participants Whose Disease Was PET Negative After 2 Cycles of Protocol Therapy Per IRF Assessment
The Deauville score according to IRF assessment of response was used to evaluate the results of PET scans. PET negative after Cycle 2 was defined as an IRF Deauville score of (1 or 2 or 3). This outcome measure was planned to be assessed only for participants treated in Phase 1 arm.
Time frame: From first dose of study drug up to Cycle 2 (Each Cycle length=28 days)
Phase 1: Percentage of Participants Whose Disease Was PET Positive After 6 Cycles of Protocol Therapy Per IRF Assessment
The Deauville score according to IRF assessment of response was used to evaluate the results of PET scans. PET positive after Cycle 6 defined as an IRF Deauville score of (4 or 5). This outcome measure was planned to be assessed only for participants treated in Phase 1 arm.
Time frame: From first dose of study drug up to Cycle 6 (Each Cycle length=28 days)
Phase 1: Percentage of Participants Who Were Antitherapeutic Antibody (ATA) Positive, Persistently Positive or Transiently Positive, and Neutralizing Antitherapeutic Antibody (nATA) Positive
ATA positive was defined as participants who have a positive ATA in any postbaseline sample. Transiently ATA positive was defined as participants who have positive ATA in 1 or 2 postbaseline samples. Persistently ATA positive was defined as participants who have positive ATA in more than 2 postbaseline timepoints. Transiently ATA positive was defined as participants who have positive ATA in 1 or 2 postbaseline samples. nATA positive was defined as participants who have at least one positive nATA in any postbaseline ATA positive sample. Here, percentage of participants who were transiently or persistently ATA positive are considered as ATA positive. This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.
Time frame: Up to 7 months
Phase 2: Progression-free Survival (PFS)
PFS per IRF:time from first dose until disease progression per IRF/death due to any cause,whichever occurred first.Participants with no objective progressive disease (PD),did not die,were still on study follow-up at time of analysis were removed from study prior to documentation of PD,PFS was censored on date of last adequate disease assessment before initiation of any non-protocol,alternative therapy.Participants who were on antitumor treatment,other than SCT/radiotherapy,censoring was at last adequate disease assessment before initiation of such alternative treatment.If participant experienced disease progression per IRF/died after initiation of antitumor treatment,other than SCT/radiotherapy,such participant was censored and not considered having PFS.Outcome measure was planned to be assessed for all participant treated at recommended dose in Phase 2.As per SAP,Phase 2 data was summarized and reported in two arms:Phase 2 and Phase 1 + Phase 2.
Time frame: Up to 24 months
Phase 2: Event-free Survival (EFS)
EFS:Time from first dose until any treatment failure:PD per IRF including progression events during follow-up period,failing to complete 6 cycles of treatment due to any reason or death due to any cause,whichever occurred first.EFS per IRF were censored on last adequate disease assessment date per IRF if none of above events occur during study.Participants with antitumor treatment,other than SCT/radiotherapy as part of frontline treatment were censored at last adequate disease assessment before initiation of such alternative treatment.If a participant experienced disease progression per IRF/died after initiation of antitumor treatment,other than SCT/radiotherapy,such participant was censored,and not be considered having EFS.This outcome measure was planned to be assessed for all patients treated at recommended dose in Phase 2.As prespecified in SAP,data for Phase 2 was summarized and reported in two arms:Phase 2 and Phase 1 + Phase 2.
Time frame: Up to 24 months
Phase 2: Overall Survival (OS)
Overall survival was defined as time from first dose until death. In the absence of confirmation of death, survival time was censored at the last date the participant was known to be alive, including study closure. This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
Time frame: Up to 24 months
Phase 2: Duration of Response (DOR)
DOR per IRF in participants with a response (CR or PR per IRF) was defined as the time from start of the first objective tumor response (CR or PR per IRF) to the first subsequent PD or death due to any cause, whichever occurred first. For patients who did not have an objective PD, did not die and are either still on a study follow-up at the time of the analysis, or were removed from the study prior to documentation of PD, DOR has been censored on the date of last adequate disease assessment. This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
Time frame: Up to 24 months
Phase 2: Percentage of Participants Receiving Irradiation for HL Following Study Treatment
This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
Time frame: Up to 24 months
Phase 2: Percentage of Participants Who Experienced AEs From the First Dose of Protocol Therapy Through 30 Days After Administration of the Last Dose of Protocol Therapy
This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
Time frame: From first dose in Cycle 1 Day 1 until 30 days after the last dose of study drug in Cycle 6 Day 15 (up to Cycle 7 Day 15) (Cycle length=28 days)
Phase 2: Percentage of Participants Who Experienced SAEs From the First Dose of Protocol Therapy Through 30 Days After Administration of the Last Dose of Protocol Therapy
This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
Time frame: From first dose in Cycle 1 Day 1 until 30 days after the last dose of study drug in Cycle 6 Day 15 (up to Cycle 7 Day 15) (Cycle length=28 days)
Phase 2: Percentage of Participants Who Were ATA Positive, Persistently Positive, or Transiently Positive, and nATA Positive
ATA positive was defined as participants who have a positive ATA in any postbaseline sample. Transiently ATA positive was defined as participants who have positive ATA in 1 or 2 postbaseline samples. Persistently ATA positive was defined as participants who have positive ATA in more than 2 postbaseline timepoints. Transiently ATA positive was defined as participants who have positive ATA in 1 or 2 postbaseline samples. nATA positive was defined as participants who have at least one positive nATA in any postbaseline ATA positive sample. Here, percentage of participants who were transiently or persistently ATA positive are considered as ATA positive. This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
Time frame: From first dose until 30 days after the last dose of study drug (up to 7 months)
Phase 2: Mean Serum Cmax of Brentuximab Vedotin and TAb
This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
Time frame: Days 1 and 15 of Cycles 1 and 3 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)
Phase 2: Mean Plasma Cmax of MMAE
This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
Time frame: Days 1 and 15 of Cycles 1 and 3 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)
Phase 2: Mean Serum AUC0-15d of Brentuximab Vedotin and TAb
This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
Time frame: Days 1 and 15 of Cycles 1 and 3 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)
Phase 2: Mean Plasma AUC0-15 of MMAE
This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
Time frame: Days 1 and 15 of Cycles 1 and 3 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)
Phase 2: Median Tmax of Brentuximab Vedotin and TAb in Serum
This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
Time frame: Days 1 and 15 of Cycles 1 and 3 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)
Phase 2: Median Tmax of MMAE in Plasma
This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
Time frame: Days 1 and 15 of Cycles 1 and 3 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)
Phase 2: Percentage of Participants Who Experienced Peripheral Neuropathy, Regardless of Seriousness, From the First Dose of Protocol Therapy
Peripheral Neuropathy (PN) was defined by the peripheral neuropathy standardized MedDRA query (SMQ) broad search. This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
Time frame: Up to 24 months
Phase 2: Time to Onset and Resolution for All Peripheral Neuropathy Events
Time to onset of first event was defined as time from first dose of study drug to onset of first treatment-emergent PN event. Time to resolution was calculated as the time from onset date to the date of resolution PN (SMQ) event. Participants with multiple resolved events were counted once at the longest time to resolution. Resolution was defined as an event outcome of resolved or resolved with sequelae. This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
Time frame: Up to 24 months
Phase 2: Immune Reconstitution-Change From Baseline Immunoglobulin G Levels at End of Treatment (EOT)
This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
Time frame: Baseline and End of Treatment (Month 7)
Phase 1: Percentage of Participants With Low and High ATA Titer Values
High ATA titer was defined as participants who have at least one postbaseline ATA titer less than (\>) 25. Low ATA titer was defined as participants whose postbaseline ATA titer are all less than or equal to (\<=) 25. This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.
Time frame: Up to 6 months
Phase 2: Percentage of Participants With Low and High ATA Titer Values
High ATA titer was defined as participants who have at least one postbaseline ATA titer \>25. Low ATA titer was defined as participants whose postbaseline ATA titer are all \<=25. This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
Time frame: Up to 6 months
Phase 1: Mean Cmax of Brentuximab Vedotin in ATA Positive and ATA Negative Participants
This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.
Time frame: Cycle 1 and 3: Days 1 and 15 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)
Phase 1: Mean AUC 0-15d of Brentuximab Vedotin in ATA Positive and ATA Negative Participants
This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.
Time frame: Cycle 1 and 3: Days 1 and 15 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)
Phase 1: Percentage of Participants Achieving CR Per IRF Assessment Per IWG Criteria in ATA Positive and ATA Negative Participants
CR was defined as the disappearance of all evidence of disease as assessed by IRF as per IWG Criteria. The data is reported per ATA status as categories. This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.
Time frame: Up to 24 months
Phase 1: Number of ATA Positive and ATA Negative Participants With AEs and SAEs
This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.
Time frame: Up to 24 months
Phase 2: Mean Cmax of Brentuximab Vedotin in ATA Positive and ATA Negative Participants
This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
Time frame: Cycle 1-3: Days 1 and 15 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)
Phase 2: Mean AUC 0-15 of Brentuximab Vedotin in ATA Positive and ATA Negative Participants
This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
Time frame: Cycle 1-3: Days 1 and 15 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)
Phase 2: Percentage of Participants Achieving CR Per IRF Assessment Per IWG Criteria in ATA Positive and ATA Negative Participants
CR is defined as the disappearance of all evidence of disease as assessed by IRF as per IWG Criteria. This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
Time frame: Up to 24 months
Phase 2: Number of ATA Positive and ATA Negative Participants With AEs and SAEs
This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
Time frame: Up to 24 months
Phase 2: Immune Reconstitution-Change From Baseline in Immunoglobulin M at the End of Treatment (EOT)
This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
Time frame: Baseline, EOT [Month 7]
Phase 2: Immune Reconstitution-Change From Baseline in Immunoglobulin A at EOT
This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
Time frame: Baseline, EOT [Month 7]
Phase 2: Immune Reconstitution-Change From Baseline in Tetanus at EOT
This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
Time frame: Baseline, EOT [Month 7]
Phase 2: Immune Reconstitution-Change From Baseline in Haemophilus Influenzae B Antibody, IgG at EOT
This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
Time frame: Baseline, EOT [Month 7]
Phase 2: Immune Reconstitution-Change From Baseline Poliovirus Antibodies Ratio at EOT
This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
Time frame: Baseline, EOT [Month 7]
Phase 2: Immune Reconstitution-Change From Baseline Total Immunoglobulin at EOT
This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
Time frame: Baseline, EOT [Month 7]
Phase 2: Immune Reconstitution-Change From Baseline in Peripheral Blood CD34+A at EOT
This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
Time frame: Baseline, EOT [Month 7]
Phase 2: Immune Reconstitution-Change From Baseline in Total Lymphocyte Count at EOT
This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
Time frame: Baseline, EOT [Month 7]
Phase 2: Immune Reconstitution-Change From Baseline in the Percentage of CD4+ (CD4+CD45RA-CD197- and CD4+CD45RA+CD197+) Subset of Cells at EOT
This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
Time frame: Baseline, EOT [Month 7]
Phase 2: Immune Reconstitution-Change From Baseline in the Percentage of CD8+ (CD8+CD45RA-CD197- and CD8+CD45RA-CD197+) Subset of Cells at EOT
This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
Time frame: Baseline, EOT [Month 7]
Participants with advanced stage newly diagnosed, classical CD30+ Hodgkin Lymphoma (HL) took part in the study at 14 investigative sites in the United States, Italy, Brazil and Japan from 06 September 2017 to data cut-off date: 24 September 2021. This study is ongoing for Post-Treatment Follow-Up (which includes Progression-Free Survival Follow-Up \[PFSFU\] and Overall Survival Follow-Up \[OSFU\]) and optional Long-Term Safety Follow-up.
| Milestone | Phase 1: Brentuximab Vedotin 48 mg/m^2 + AVD | Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD |
|---|---|---|
| Started | 8 | 51 |
| Completed | 0 | 0 |
| Not completed | 8 | 51 |
| Withdrew: Post-treatment follow-up (pfsfu and osfu) | 0 | 28 |
| Withdrew: Particpants ongoing in long-term safety follow-up | 8 | 23 |
The recommended dose was determined after considering all safety data in phase 1 and assessing for dose limiting toxicities (DLTs) which are defined as the dose range at which less than or equal to (\<=) 1 of 6 evaluable participants experience DLT within the defined observation period (Cycle 1 + 28 days). This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.
| mg/m^2 | Phase 1: Brentuximab Vedotin 48 mg/m^2 +AVD |
|---|---|
| Phase 1: Recommended Dose of Brentuximab Vedotin in Combination With Doxorubicin, Vinblastine, and Dacarbazine in a Pediatric Population | 48 |
AE means any untoward medical occurrence in a participant administered a pharmaceutical product; the untoward medical occurrence does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product whether or not it is related to the medicinal product. This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.
| percentage of participants | Phase 1: Brentuximab Vedotin 48 mg/m^2 +AVD |
|---|---|
| Phase 1: Percentage of Participants Who Experienced Adverse Events (AEs) From the First Dose of Protocol Therapy Through 30 Days After Administration of the Last Dose of Protocol Therapy | 100 |
AE means any untoward medical occurrence in a participant administered a pharmaceutical product; the untoward medical occurrence does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product whether or not it is related to the medicinal product. SAE is defined as any untoward medical occurrence that at any dose results in death, Is life-threatening, requires inpatient hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability or incapacity, Is a congenital anomaly/birth defect, Is a medically important event.
| percentage of participants | Phase 1: Brentuximab Vedotin 48 mg/m^2 +AVD |
|---|---|
| Phase 1: Percentage of Participants Who Experienced Serious Adverse Events (SAEs) From the First Dose of Protocol Therapy Through 30 Days After Administration of the Last Dose of Protocol Therapy | 13 |
CR was defined as the disappearance of all evidence of disease as assessed by IRF as per IWG Criteria. The confidence interval was based on exact binomial distribution (Clopper-Pearson method). This outcome measure was planned to be assessed for all participants treated at the recommended dose in Phase 2. As prespecified in the statistical analysis plan (SAP) , data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
| percentage of participants | Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD | Phase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD |
|---|---|---|
| Phase 2: Percentage of Participants Who Achieved a Complete Remission (CR) Per Independent Review Facility (IRF) Assessment Per International Working Group (IWG) Criteria at End of Treatment (EOT) Visit | 75 (60 to 86) | 76 (63 to 86) |
The Deauville score according to IRF assessment of response was used to evaluate the results of PET scans. PET negative after Cycle 2 was defined as an IRF Deauville score of (1 or 2 or 3). This outcome measure was planned to be assessed for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
| percentage of participants | Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD | Phase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD |
|---|---|---|
| Phase 2: Percentage of Participants Whose Disease Was Positron Emission Tomography (PET) Negative After 2 Cycles of Protocol Therapy Per IRF Assessment | 90 | 90 |
PR was defined as regression of measurable disease and no new sites as assessed by IRF as per IWG criteria. Percentage of participants in the response-evaluable population who achieved a partial response based on the IRF assessment at the EOT visit based on the IWG criteria are reported. The confidence interval was based on exact binomial distribution (Clopper-Pearson method). This outcome measure was planned to be assessed for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
| percentage of participants | Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD | Phase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD |
|---|---|---|
| Phase 2: Percentage of Participants Who Achieved a Partial Remission (PR) Per IRF Assessment Per IWG Criteria at EOT Visit | 12 (6 to 20) | 12 (5 to 23) |
Overall response rate was defined as the percentage of participants with CR or PR as assessed by IRF using IWG criteria. CR was defined as the disappearance of all evidence of disease and PR was defined as regression of measurable disease and no new diseases. The confidence interval was based on exact binomial distribution (Clopper-Pearson method). This outcome measure was planned to be assessed for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
| percentage of participants | Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD | Phase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD |
|---|---|---|
| Phase 2: Percentage of Participants Who Achieved an Overall Response Rate (ORR) Per IRF Assessment Per IWG Criteria at EOT Visit | 86 (74 to 94) | 88 (77 to 95) |
This outcome measure was planned to be assessed for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
| percentage of participants | Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD | Phase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD |
|---|---|---|
| Phase 2: Percentage of Participants Who Were Able to Complete 6 Cycles of Protocol Therapy at the Recommended Dose | 100 | 100 |
This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.
| microgram per milliliter(mcg/mL) | Phase 1: Brentuximab Vedotin 48 mg/m^2 +AVD |
|---|---|
| Conjugate Brentuximab Vedotin at Cycle 1 Day 1 | 22.6 ± 1.51 |
| Conjugate Brentuximab Vedotin at Cycle 1 Day 15 | 23.1 ± 3.85 |
| Conjugate Brentuximab Vedotin at Cycle 3 Day 1 | 26.7 ± 3.65 |
| Conjugate Brentuximab Vedotin at Cycle 3 Day 15 | 27.3 ± 7.14 |
| TAb at Cycle 1 Day 1 | 24.9 ± 3.84 |
| TAb at Cycle 1 Day 15 | 25.5 ± 5.28 |
| TAb at Cycle 3 Day 1 | 29.6 ± 4.05 |
| TAb at Cycle 3 Day 15 | 28.1 ± 7.45 |
This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.
| nanogram per milliliter (ng/ml) | Phase 1: Brentuximab Vedotin 48 mg/m^2 +AVD |
|---|---|
| Cycle 1 Day 1 | 5.51 ± 3.91 |
| Cycle 1 Day 15 | 2.08 ± 0.677 |
| Cycle 3 Day 1 | 1.38 ± 0.514 |
| Cycle 3 Day 15 | 1.19 ± 0.366 |
This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.
| day*microgram per milliliter(day*mcg/mL) | Phase 1: Brentuximab Vedotin 48 mg/m^2 +AVD |
|---|---|
| AUC0-15d of Brentuximab Vedotin at Cycle 1 Day 1 | 42.3 ± 3.10 |
| AUC0-15d of Brentuximab Vedotin at Cycle 1 Day 15 | 48.8 ± 5.83 |
| AUC0-15d of Brentuximab Vedotin at Cycle 3 Day 1 | 72.7 ± 27.8 |
| AUC0-15d of Brentuximab Vedotin at Cycle 3 Day 15 | 64.8 ± 13.5 |
| AUC0-15d of TAb at Cycle 1 Day 1 | 80.6 ± 13.0 |
| AUC0-15d of TAb at Cycle 1 Day 15 | 103 ± 14.6 |
| AUC0-15d of TAb at Cycle 3 Day 1 | 127 ± 10.2 |
| AUC0-15d of TAb at Cycle 3 Day 15 | 128 ± 34.4 |
This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.
| day* nanogram per milliliter (day*ng/mL) | Phase 1: Brentuximab Vedotin 48 mg/m^2 +AVD |
|---|---|
| Cycle 1 Day 1 | 29.8 ± 21.2 |
| Cycle 1 Day 15 | 13.1 ± 2.99 |
| Cycle 3 Day 1 | 8.88 ± 2.53 |
| Cycle 3 Day 15 | 7.17 ± 2.17 |
This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.
| hour | Phase 1: Brentuximab Vedotin 48 mg/m^2 +AVD |
|---|---|
| Tmax of Brentuximab Vedotin at Cycle 1 Day 1 | 1.00 (0.570 to 1.05) |
| Tmax of Brentuximab Vedotin at Cycle 1 Day 15 | 0.915 (0.580 to 1.00) |
| Tmax of Brentuximab Vedotin at Cycle 3 Day 1 | 1.00 (0.630 to 1.17) |
| Tmax of Brentuximab Vedotin at Cycle 3 Day 15 | 0.830 (0.580 to 1.00) |
| Tmax of TAb at Cycle 1 Day 1 | 1.00 (0.570 to 1.05) |
| Tmax of TAb at Cycle 1 Day 15 | 0.915 (0.580 to 1.00) |
This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.
| hour | Phase 1: Brentuximab Vedotin 48 mg/m^2 +AVD |
|---|---|
| Cycle 1 Day 1 | 44.9 (21.1 to 69.1) |
| Cycle 1 Day 15 | 43.1 (41.2 to 45.9) |
| Cycle 3 Day 1 | 48.0 (42.3 to 66.9) |
| Cycle 3 Day 15 | 48.2 (20.8 to 67.0) |
CR was defined as the disappearance of all evidence of disease as assessed by IRF as per IWG Criteria. The confidence interval was based on exact binomial distribution (Clopper-Pearson method). This outcome measure was planned to be assessed only for participants treated in Phase 1 arm.
| percentage of participants | Phase 1: Brentuximab Vedotin 48 mg/m^2 +AVD |
|---|---|
| Phase 1: Percentage of Participants Who Achieved a CR Per IRF Assessment Per IWG Criteria at EOT Visit | 88 (47 to 100) |
PR was defined as regression of measurable disease and no new diseases as per IWG Criteria based on IRF. The confidence interval was based on exact binomial distribution (Clopper-Pearson method). This outcome measure was planned to be assessed only for participants treated in Phase 1 arm.
| percentage of participants | Phase 1: Brentuximab Vedotin 48 mg/m^2 +AVD |
|---|---|
| Phase 1: Percentage of Participants Who Achieved a PR Per IRF Assessment Per IWG Criteria at EOT Visit | 13 (1 to 53) |
Overall response rate was defined as the percentage of participants with CR or PR as assessed by an IRF using IWG Revised Response Criteria. CR was defined as the disappearance of all evidence of disease and PR was defined as regression of measurable disease and no new sites. The confidence interval was based on exact binomial distribution (Clopper-Pearson method). This outcome measure was planned to be assessed only for participants treated in Phase 1 arm.
| percentage of participants | Phase 1: Brentuximab Vedotin 48 mg/m^2 +AVD |
|---|---|
| Phase 1: Percentage of Participants Who Achieved an ORR Per IRF Assessment Per IWG Criteria at EOT Visit | 100 (63 to 100) |
The Deauville score according to IRF assessment of response was used to evaluate the results of PET scans. PET negative after Cycle 2 was defined as an IRF Deauville score of (1 or 2 or 3). This outcome measure was planned to be assessed only for participants treated in Phase 1 arm.
| percentage of participants | Phase 1: Brentuximab Vedotin 48 mg/m^2 +AVD |
|---|---|
| Phase 1: Percentage of Participants Whose Disease Was PET Negative After 2 Cycles of Protocol Therapy Per IRF Assessment | 88 (47 to 100) |
The Deauville score according to IRF assessment of response was used to evaluate the results of PET scans. PET positive after Cycle 6 defined as an IRF Deauville score of (4 or 5). This outcome measure was planned to be assessed only for participants treated in Phase 1 arm.
| percentage of participants | Phase 1: Brentuximab Vedotin 48 mg/m^2 +AVD |
|---|---|
| Phase 1: Percentage of Participants Whose Disease Was PET Positive After 6 Cycles of Protocol Therapy Per IRF Assessment | 13 (1 to 53) |
ATA positive was defined as participants who have a positive ATA in any postbaseline sample. Transiently ATA positive was defined as participants who have positive ATA in 1 or 2 postbaseline samples. Persistently ATA positive was defined as participants who have positive ATA in more than 2 postbaseline timepoints. Transiently ATA positive was defined as participants who have positive ATA in 1 or 2 postbaseline samples. nATA positive was defined as participants who have at least one positive nATA in any postbaseline ATA positive sample. Here, percentage of participants who were transiently or persistently ATA positive are considered as ATA positive. This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.
| percentage of participants | Phase 1: Brentuximab Vedotin 48 mg/m^2 +AVD |
|---|---|
| Transiently ATA Positive | 13 |
| Persistently ATA Positive | 0 |
| nATA Positive | 0 |
PFS per IRF:time from first dose until disease progression per IRF/death due to any cause,whichever occurred first.Participants with no objective progressive disease (PD),did not die,were still on study follow-up at time of analysis were removed from study prior to documentation of PD,PFS was censored on date of last adequate disease assessment before initiation of any non-protocol,alternative therapy.Participants who were on antitumor treatment,other than SCT/radiotherapy,censoring was at last adequate disease assessment before initiation of such alternative treatment.If participant experienced disease progression per IRF/died after initiation of antitumor treatment,other than SCT/radiotherapy,such participant was censored and not considered having PFS.Outcome measure was planned to be assessed for all participant treated at recommended dose in Phase 2.As per SAP,Phase 2 data was summarized and reported in two arms:Phase 2 and Phase 1 + Phase 2.
| months | Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD | Phase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD |
|---|---|---|
| Phase 2: Progression-free Survival (PFS) | NA (NA to NA) | NA (NA to NA) |
EFS:Time from first dose until any treatment failure:PD per IRF including progression events during follow-up period,failing to complete 6 cycles of treatment due to any reason or death due to any cause,whichever occurred first.EFS per IRF were censored on last adequate disease assessment date per IRF if none of above events occur during study.Participants with antitumor treatment,other than SCT/radiotherapy as part of frontline treatment were censored at last adequate disease assessment before initiation of such alternative treatment.If a participant experienced disease progression per IRF/died after initiation of antitumor treatment,other than SCT/radiotherapy,such participant was censored,and not be considered having EFS.This outcome measure was planned to be assessed for all patients treated at recommended dose in Phase 2.As prespecified in SAP,data for Phase 2 was summarized and reported in two arms:Phase 2 and Phase 1 + Phase 2.
| months | Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD | Phase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD |
|---|---|---|
| Phase 2: Event-free Survival (EFS) | NA (NA to NA) | NA (NA to NA) |
Overall survival was defined as time from first dose until death. In the absence of confirmation of death, survival time was censored at the last date the participant was known to be alive, including study closure. This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
| months | Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD | Phase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD |
|---|---|---|
| Phase 2: Overall Survival (OS) | NA (NA to NA) | NA (NA to NA) |
DOR per IRF in participants with a response (CR or PR per IRF) was defined as the time from start of the first objective tumor response (CR or PR per IRF) to the first subsequent PD or death due to any cause, whichever occurred first. For patients who did not have an objective PD, did not die and are either still on a study follow-up at the time of the analysis, or were removed from the study prior to documentation of PD, DOR has been censored on the date of last adequate disease assessment. This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
| months | Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD | Phase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD |
|---|---|---|
| Phase 2: Duration of Response (DOR) | NA (NA to NA) | NA (NA to NA) |
This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
| percentage of participants | Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD | Phase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD |
|---|---|---|
| Phase 2: Percentage of Participants Receiving Irradiation for HL Following Study Treatment | 25 (14 to 40) | 24 (14 to 37) |
This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
| percentage of participants | Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD | Phase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD |
|---|---|---|
| Phase 2: Percentage of Participants Who Experienced AEs From the First Dose of Protocol Therapy Through 30 Days After Administration of the Last Dose of Protocol Therapy | 100 | 100 |
This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
| percentage of participants | Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD | Phase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD |
|---|---|---|
| Phase 2: Percentage of Participants Who Experienced SAEs From the First Dose of Protocol Therapy Through 30 Days After Administration of the Last Dose of Protocol Therapy | 45 | 41 |
ATA positive was defined as participants who have a positive ATA in any postbaseline sample. Transiently ATA positive was defined as participants who have positive ATA in 1 or 2 postbaseline samples. Persistently ATA positive was defined as participants who have positive ATA in more than 2 postbaseline timepoints. Transiently ATA positive was defined as participants who have positive ATA in 1 or 2 postbaseline samples. nATA positive was defined as participants who have at least one positive nATA in any postbaseline ATA positive sample. Here, percentage of participants who were transiently or persistently ATA positive are considered as ATA positive. This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
| percentage of participants | Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD | Phase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD |
|---|---|---|
| Transiently ATA Positive | 6 | 7 |
| Persistently ATA Positive | 0 | 0 |
| nATA Positive | 4 | 3 |
This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
| µg/mL | Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD | Phase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD |
|---|---|---|
| Cmax of Brentuximab Vedotin at Cycle 1 Day 1 | 23.1 ± 5.54 | 23.0 ± 5.21 |
| Cmax of Brentuximab Vedotin at Cycle 1 Day 15 | 25.3 ± 5.12 | 24.9 ± 4.97 |
| Cmax of Brentuximab Vedotin at Cycle 3 Day 1 | 27.4 ± 6.14 | 27.3 ± 5.82 |
| Cmax of Brentuximab Vedotin at Cycle 3 Day 15 | 25.4 ± 4.03 | 25.8 ± 4.81 |
| Cmax of TAb Vedotin at Cycle 1 Day 1 | 22.1 ± 5.34 | 22.4 ± 5.23 |
| Cmax of TAb Vedotin at Cycle 1 Day 15 | 26.5 ± 9.02 | 26.4 ± 8.52 |
| Cmax of TAb Vedotin at Cycle 3 Day 1 | 29.5 ± 8.89 | 29.5 ± 8.44 |
| Cmax of TAb Vedotin at Cycle 3 Day 15 | 32.2 ± 11.0 | 31.4 ± 10.4 |
This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
| ng/mL | Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD | Phase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD |
|---|---|---|
| Cycle 1 Day 1 | 5.49 ± 2.62 | 5.49 ± 2.80 |
| Cycle 1 Day 15 | 2.95 ± 1.66 | 2.81 ± 1.57 |
| Cycle 3 Day 1 | 1.75 ± 0.643 | 1.69 ± 0.635 |
| Cycle 3 Day 15 | 1.74 ± 0.599 | 1.61 ± 0.597 |
This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
| day*µg/mL | Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD | Phase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD |
|---|---|---|
| AUC0-15d of Brentuximab Vedotin at Cycle 1 Day 1 | 49.7 ± 17.2 | 48.8 ± 16.3 |
| AUC0-15d of Brentuximab Vedotin at Cycle 1 Day 15 | 54.9 ± 22.2 | 54.0 ± 20.6 |
| AUC0-15d of Brentuximab Vedotin at Cycle 3 Day 1 | 62.6 ± 16.9 | 63.9 ± 18.6 |
| AUC0-15d of Brentuximab Vedotin at Cycle 3 Day 15 | 60.6 ± 11.1 | 61.4 ± 11.5 |
| AUC0-15d of TAb at Cycle 1 Day 1 | 77.2 ± 18.6 | 77.6 ± 18.0 |
| AUC0-15d of TAb at Cycle 1 Day 15 | 97.3 ± 28.7 | 98.1 ± 27.0 |
| AUC0-15d of TAb at Cycle 3 Day 1 | 119 ± 30.6 | 120 ± 29.1 |
| AUC0-15d of TAb at Cycle 3 Day 15 | 124 ± 21.6 | 125 ± 24.1 |
This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
| day*ng/mL | Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD | Phase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD |
|---|---|---|
| Cycle 1 Day 1 | 31.2 ± 16.2 | 31.0 ± 16.8 |
| Cycle 1 Day 15 | 18.4 ± 11.9 | 17.9 ± 11.4 |
| Cycle 3 Day 1 | 11.5 ± 5.16 | 11.1 ± 4.93 |
| Cycle 3 Day 15 | 12.3 ± 6.12 | 11.3 ± 5.90 |
This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
| hour | Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD | Phase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD |
|---|---|---|
| Tmax of Brentuximab Vedotin at Cycle 1 Day 1 | 1.03 (0.530 to 164) | 1.00 (0.530 to 164) |
| Tmax of Brentuximab Vedotin at Cycle 1 Day 15 | 1.00 (0.500 to 22.7) | 1.00 (0.500 to 22.7) |
| Tmax of Brentuximab Vedotin at Cycle 3 Day 1 | 1.00 (0.00 to 23.0) | 1.00 (0.00 to 23.0) |
| Tmax of Brentuximab Vedotin at Cycle 3 Day 15 | 1.00 (0.520 to 1.50) | 1.00 (0.520 to 1.50) |
| Tmax of TAb at Cycle 1 Day 1 | 1.01 (0.530 to 20.8) | 1.00 (0.530 to 20.8) |
| Tmax of TAb at Cycle 1 Day 15 | 1.00 (0.500 to 334) | 1.00 (0.500 to 334) |
| Tmax of TAb at Cycle 3 Day 1 | 1.00 (0.00 to 23.3) | 1.00 (0.00 to 23.3) |
| Tmax of TAb at Cycle 3 Day 15 | 1.00 (0.520 to 1.50) | 1.00 (0.520 to 1.50) |
This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
| hour | Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD | Phase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD |
|---|---|---|
| Cycle 1 Day 1 | 44.1 (19.7 to 72.0) | 44.4 (19.7 to 72.0) |
| Cycle 1 Day 15 | 42.9 (20.0 to 72.0) | 42.9 (20.0 to 72.0) |
| Cycle 3 Day 1 | 44.9 (20.3 to 71.7) | 45.3 (20.3 to 71.7) |
| Cycle 3 Day 15 | 45.4 (20.0 to 71.7) | 46.0 (20.0 to 71.7) |
Peripheral Neuropathy (PN) was defined by the peripheral neuropathy standardized MedDRA query (SMQ) broad search. This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
| percentage of participants | Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD | Phase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD |
|---|---|---|
| Phase 2: Percentage of Participants Who Experienced Peripheral Neuropathy, Regardless of Seriousness, From the First Dose of Protocol Therapy | 20 | 19 |
Time to onset of first event was defined as time from first dose of study drug to onset of first treatment-emergent PN event. Time to resolution was calculated as the time from onset date to the date of resolution PN (SMQ) event. Participants with multiple resolved events were counted once at the longest time to resolution. Resolution was defined as an event outcome of resolved or resolved with sequelae. This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
| weeks | Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD | Phase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD |
|---|---|---|
| Time to Onset | 5.93 (0.9 to 19.9) | 5.93 (0.9 to 19.9) |
| Time to Resolution | 1.57 (0.3 to 100.3) | 1.57 (0.3 to 100.3) |
This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
| g/L | Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD | Phase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD |
|---|---|---|
| Baseline | 16.518 ± 5.5306 | 16.217 ± 5.2175 |
| Change from Baseline at EOT | -4.822 ± 4.8964 | -4.675 ± 4.7204 |
High ATA titer was defined as participants who have at least one postbaseline ATA titer less than (\>) 25. Low ATA titer was defined as participants whose postbaseline ATA titer are all less than or equal to (\<=) 25. This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.
| percentage of participants | Phase 1: Brentuximab Vedotin 48 mg/m^2 + AVD |
|---|---|
| ATA Titer low | 13 |
| ATA Titer High | 0 |
High ATA titer was defined as participants who have at least one postbaseline ATA titer \>25. Low ATA titer was defined as participants whose postbaseline ATA titer are all \<=25. This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
| percentage of participants | Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD | Phase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD |
|---|---|---|
| ATA Titer Low | 6 | 7 |
| ATA Titer High | 0 | 0 |
This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.
| µg/mL | Phase 1: Brentuximab Vedotin 48 mg/m^2 + AVD |
|---|---|
| ATA Positive: Cycle 1 Day 1 | 23.3 ± NA |
| ATA Positive: Cycle 1 Day 15 | 21.1 ± NA |
| ATA Positive: Cycle 3 Day 1 | 23.1 ± NA |
| ATA Positive: Cycle 3 Day 15 | 21.6 ± NA |
| ATA Negative: Cycle 1 Day 1 | 22.5 ± 1.62 |
| ATA Negative: Cycle 1 Day 15 | 23.5 ± 4.17 |
| ATA Negative: Cycle 3 Day 1 | 27.2 ± 3.62 |
| ATA Negative: Cycle 3 Day 15 | 28.3 ± 7.32 |
This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.
| day*µg/mL | Phase 1: Brentuximab Vedotin 48 mg/m^2 + AVD |
|---|---|
| ATA Positive: Cycle 1 Day 1 | 42.4 ± NA |
| ATA Positive: Cycle 1 Day 15 | 50.0 ± NA |
| ATA Positive: Cycle 3 Day 1 | 56.6 ± NA |
| ATA Positive: Cycle 3 Day 15 | 63.0 ± NA |
| ATA Negative: Cycle 1 Day 1 | 42.2 ± 3.40 |
| ATA Negative: Cycle 1 Day 15 | 48.6 ± 6.48 |
| ATA Negative: Cycle 3 Day 1 | 75.4 ± 29.46 |
| ATA Negative: Cycle 3 Day 15 | 65.1 ± 15.06 |
CR was defined as the disappearance of all evidence of disease as assessed by IRF as per IWG Criteria. The data is reported per ATA status as categories. This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.
| percentage of participants | Phase 1: Brentuximab Vedotin 48 mg/m^2 + AVD |
|---|---|
| ATA Negative who Achieved CR | 86 (42 to 100) |
| Transiently ATA Positive who Achieved CR | 100 (3 to 100) |
This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.
| Participants | Phase 1: Brentuximab Vedotin 48 mg/m^2 + AVD |
|---|---|
| ATA Negative: AEs | 7 |
| ATA Positive: AEs | 1 |
| ATA Negative: SAEs | 0 |
| ATA Positive: SAEs | 1 |
This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
| µg/mL | Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD | Phase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD |
|---|---|---|
| ATA Positive: Cycle 1 Day 1 | 27.8 ± 8.56 | 26.7 ± 7.34 |
| ATA Positive: Cycle 1 Day 15 | 23.3 ± 6.88 | 22.7 ± 5.72 |
| ATA Positive: Cycle 3 Day 1 | 22.0 ± 2.92 | 22.4 ± 2.15 |
| ATA Positive: Cycle 3 Day 15 | 25.6 ± 7.93 | 24.2 ± 6.07 |
| ATA Negative: Cycle 1 Day 1 | 22.8 ± 5.29 | 22.7 ± 5.00 |
| ATA Negative: Cycle 1 Day 15 | 25.4 ± 5.02 | 25.2 ± 4.91 |
| ATA Negative: Cycle 3 Day 1 | 27.7 ± 6.14 | 27.6 ± 5.84 |
| ATA Negative: Cycle 3 Day 15 | 25.4 ± 3.85 | 26.0 ± 4.76 |
This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
| day*µg/mL | Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD | Phase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD |
|---|---|---|
| ATA Positive: Cycle 1 Day 1 | 51.6 ± 17.17 | 49.3 ± 14.75 |
| ATA Positive: Cycle 1 Day 15 | 45.6 ± 38.87 | 46.7 ± 31.81 |
| ATA Positive: Cycle 3 Day 1 | 53.7 ± 10.16 | 54.6 ± 7.38 |
| ATA Positive: Cycle 3 Day 15 | 57.2 ± 12.37 | 59.1 ± 9.38 |
| ATA Negative: Cycle 1 Day 1 | 49.6 ± 17.41 | 48.8 ± 16.58 |
| ATA Negative: Cycle 1 Day 15 | 55.8 ± 20.77 | 54.8 ± 19.52 |
| ATA Negative: Cycle 3 Day 1 | 63.0 ± 17.10 | 64.4 ± 18.99 |
| ATA Negative: Cycle 3 Day 15 | 60.9 ± 11.23 | 61.7 ± 11.81 |
CR is defined as the disappearance of all evidence of disease as assessed by IRF as per IWG Criteria. This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
| percentage of participants | Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD | Phase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD |
|---|---|---|
| ATA Negative | 75 (60 to 86) | 76 (63 to 87) |
| Transiently ATA Positive | 67 (9 to 99) | 75 (19 to 99) |
This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
| Participants | Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD | Phase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD |
|---|---|---|
| ATA Negative: AEs | 48 | 55 |
| ATA Positive: AEs | 3 | 4 |
| ATA Negative: SAEs | 21 | 21 |
| ATA Positive: SAEs | 2 | 3 |
This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
| g/L | Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD | Phase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD |
|---|---|---|
| Baseline | 1.275 ± 0.5065 | 1.261 ± 0.4824 |
| Change at EOT (Month 7) | -0.345 ± 0.5942 | -0.375 ± 0.5766 |
This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
| g/L | Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD | Phase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD |
|---|---|---|
| Baseline | 2.708 ± 1.2379 | 2.671 ± 1.1879 |
| Change from Baseline at EOT | -0.195 ± 1.0479 | -0.125 ± 1.0844 |
This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
| (IU)/mL | Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD | Phase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD |
|---|---|---|
| Baseline | 1.636 ± 2.5600 | 1.935 ± 3.0358 |
| Change from Baseline at EOT | -0.648 ± 1.3412 | -0.914 ± 2.2679 |
This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
| µg/mL | Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD | Phase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD |
|---|---|---|
| Baseline | 10.39 ± 27.017 | 9.50 ± 25.167 |
| Change from Baseline at EOT | -7.00 ± 24.258 | -6.03 ± 23.160 |
This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
| ratio | Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD | Phase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD |
|---|---|---|
| Baseline: Type I | 0.02447 ± 0.027568 | 0.02373 ± 0.028092 |
| EOT: Type I | 0.00913 ± 0.024223 | 0.00845 ± 0.023091 |
| Baseline: Type III | 0.03641 ± 0.036709 | 0.03432 ± 0.036653 |
| EOT: Type III | 0.01141 ± 0.029889 | 0.01013 ± 0.028461 |
This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
| mg/dl | Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD | Phase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD |
|---|---|---|
| Baseline | 2086.6 ± 615.62 | 2045.1 ± 583.04 |
| Change from Baseline at EOT | -582.3 ± 565.52 | -556.3 ± 553.97 |
This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
| µL | Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD | Phase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD |
|---|---|---|
| Baseline | 4.182 ± 4.1227 | 3.917 ± 3.8917 |
| Change from Baseline at EOT | -1.512 ± 4.7075 | -1.456 ± 4.3472 |
This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
| 10^9 lymphocytes/L | Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD | Phase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD |
|---|---|---|
| Baseline | 1.8022 ± 0.95206 | 1.7408 ± 0.91394 |
| Change from Baseline at EOT | 0.6736 ± 3.77611 | 0.5965 ± 3.50121 |
This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
| percentage of CD4+ subset cells | Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD | Phase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD |
|---|---|---|
| Baseline: CD4+CD45RA-CD197- | 28.0 ± 12.76 | 29.0 ± 13.42 |
| Change from Baseline at EOT: CD4+CD45RA-CD197- | -5.0 ± 17.72 | -5.1 ± 16.44 |
| Baseline: CD4+CD45RA-CD197+ | 23.7 ± 14.33 | 22.3 ± 13.86 |
| Change from Baseline at EOT: CD4+CD45RA-CD197+ | 13.0 ± 14.14 | 12.6 ± 13.21 |
| Baseline: CD4+CD45RA+CD197- | 2.9 ± 3.41 | 3.1 ± 3.22 |
| Change from Baseline at EOT: CD4+CD45RA+CD197- | -0.7 ± 2.25 | -0.7 ± 2.41 |
| Baseline: CD4+CD45RA+CD197+ | 46.2 ± 14.44 | 46.3 ± 14.89 |
| Change from Baseline at EOT: CD4+CD45RA+CD197+ | -7.2 ± 11.60 | -6.8 ± 11.04 |
This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.
| percentage of CD8+ subset cells | Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD | Phase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD |
|---|---|---|
| Baseline: CD8+CD45RA-CD197- | 39.9 ± 19.32 | 40.6 ± 20.00 |
| Change from Baseline at EOT: CD8+CD45RA-CD197- | -11.5 ± 13.85 | -11.0 ± 14.33 |
| Baseline: CD8+CD45RA-CD197+ | 2.4 ± 1.81 | 2.3 ± 1.76 |
| Change from Baseline at EOT: CD8+CD45RA-CD197+ | 1.6 ± 2.52 | 2.1 ± 3.08 |
| Baseline: CD8+CD45RA+CD197- | 25.9 ± 15.43 | 25.8 ± 14.60 |
| Change from Baseline at EOT: CD8+CD45RA+CD197- | -6.0 ± 11.27 | -6.5 ± 11.83 |
| Baseline: CD8+CD45RA+CD197+ | 31.3 ± 18.00 | 30.8 ± 18.53 |
| Change from Baseline at EOT: CD8+CD45RA+CD197+ | 15.7 ± 11.48 | 15.4 ± 12.15 |
Collected over From first dose of study drug up to data cut -off date: 24 September 2021 (Up to approximately 4 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1: Brentuximab Vedotin 48 mg/m^2 + AVD | 0/8 (0%) | 1/8 (12.5%) | 8/8 (100%) |
| Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD | 0/51 (0%) | 23/51 (45.1%) | 51/51 (100%) |
| Event | Phase 1: Brentuximab Vedotin 48 mg/m^2 + AVD | Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD |
|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 1/8 | 9/51 |
| NeutropeniaBlood and lymphatic system disorders | 0/8 | 3/51 |
| VomitingGastrointestinal disorders | 0/8 | 3/51 |
| ConstipationGastrointestinal disorders | 0/8 | 2/51 |
| Gastrointestinal disorderGastrointestinal disorders | 0/8 | 2/51 |
| NauseaGastrointestinal disorders | 0/8 | 2/51 |
| SepsisInfections and infestations | 0/8 | 2/51 |
| PyrexiaGeneral disorders | 0/8 | 2/51 |
| AnaemiaBlood and lymphatic system disorders | 0/8 | 1/51 |
| Abdominal painGastrointestinal disorders | 0/8 | 1/51 |
| Event | Phase 1: Brentuximab Vedotin 48 mg/m^2 + AVD | Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD |
|---|---|---|
| VomitingGastrointestinal disorders | 8/8 | 42/51 |
| NauseaGastrointestinal disorders | 8/8 | 36/51 |
| Abdominal pain upperGastrointestinal disorders | 8/8 | 7/51 |
| NeutropeniaBlood and lymphatic system disorders | 8/8 | 20/51 |
| AstheniaGeneral disorders | 5/8 | 3/51 |
| White blood cell count decreasedInvestigations | 5/8 | 20/51 |
| HeadacheNervous system disorders | 5/8 | 14/51 |
| StomatitisGastrointestinal disorders | 4/8 | 21/51 |
| ConstipationGastrointestinal disorders | 4/8 | 17/51 |
| DiarrhoeaGastrointestinal disorders | 4/8 | 10/51 |
The safety population included participants who had received at least 1 dose of any study drug (A+AVD regimen).
| Age, Continuous(years) | Phase 1: Brentuximab Vedotin 48 mg/m^2 + AVD | Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD | Total |
|---|---|---|---|
| Mean | 12.4 ± 3.81 | 13.9 ± 2.88 | 13.7 ± 3.03 |
| Sex: Female, Male(Participants) | Phase 1: Brentuximab Vedotin 48 mg/m^2 + AVD | Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD | Total |
|---|---|---|---|
| Female | 4 | 24 | 28 |
| Male | 4 | 27 | 31 |
| Ethnicity (NIH/OMB)(Participants) | Phase 1: Brentuximab Vedotin 48 mg/m^2 + AVD | Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 21 | 23 |
| Not Hispanic or Latino | 6 | 26 | 32 |
| Unknown or Not Reported | 0 | 4 | 4 |
| Race/Ethnicity, Customized(Participants) | Phase 1: Brentuximab Vedotin 48 mg/m^2 + AVD | Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD | Total |
|---|---|---|---|
| Asian | 0 | 3 | 3 |
| Black or African American | 0 | 12 | 12 |
| White | 8 | 26 | 34 |
| "Brown" or "Mulatto" | 0 | 9 | 9 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Region of Enrollment(Participants) | Phase 1: Brentuximab Vedotin 48 mg/m^2 + AVD | Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD | Total |
|---|---|---|---|
| United States | 2 | 10 | 12 |
| Japan | 0 | 2 | 2 |
| Italy | 5 | 10 | 15 |
| Brazil | 1 | 29 | 30 |
| Weight(kilograms (kg)) | Phase 1: Brentuximab Vedotin 48 mg/m^2 + AVD | Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD | Total |
|---|---|---|---|
| Mean | 45.91 ± 18.867 | 49.91 ± 15.649 | 49.37 ± 16.000 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Sep 2017 to primary completion in May 2020, 31 months.
Results were first posted in Jun 2021, 1 year after primary completion.
Of 63 phase 1/2 interventional studies under Hodgkin Disease, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 53 and three quarters within 97. This study's 31 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Brentuximab Vedotin · Doxorubicin · Vinblastine · Dacarbazine